Experimental dermatologyHumansNivolumabMelanomaDouble-Blind MethodAntineoplastic Combined Chemotherapy Protocols
Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol.
Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Yasuhiro Fujisawa, Shigeto Matsushita, Hisashi Uhara, Daiki Rokunohe, Tatsuya Takenouchi, Takeo Maekawa, Yoshiyuki Nakamura, Kenjiro Namikawa, Akira Takahashi, Shusuke Yoshikawa, Hiroaki Iwata
Published: 202610.1111/exd.70202
Abstract
TM5614, a plasminogen activator inhibitor-1 (PAI-1) inhibitor, has demonstrated potential in overcoming nivolumab resistance in patients with unresectable, anti-PD-1 antibody-refractory malignant melanoma. Previous Phase II trials have shown promisin…
Preview only. Read the full abstract at the source